Ionic Capital Management LLC Cuts Stake in Globus Medical, Inc. $GMED

Ionic Capital Management LLC lowered its stake in shares of Globus Medical, Inc. (NYSE:GMED) by 32.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,596 shares of the medical device company’s stock after selling 15,000 shares during the period. Globus Medical comprises 0.4% of Ionic Capital Management LLC’s investment portfolio, making the stock its 12th biggest position. Ionic Capital Management LLC’s holdings in Globus Medical were worth $2,759,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. William Blair Investment Management LLC grew its stake in shares of Globus Medical by 17.2% in the 3rd quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock valued at $161,454,000 after buying an additional 414,134 shares during the period. ANTIPODES PARTNERS Ltd grew its stake in shares of Globus Medical by 49,020.3% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 891,043 shares of the medical device company’s stock valued at $51,034,000 after buying an additional 889,229 shares during the period. Annex Advisory Services LLC purchased a new stake in shares of Globus Medical in the 4th quarter valued at approximately $20,572,000. Kingdon Capital Management L.L.C. grew its stake in shares of Globus Medical by 51.6% in the 3rd quarter. Kingdon Capital Management L.L.C. now owns 257,650 shares of the medical device company’s stock valued at $14,756,000 after buying an additional 87,650 shares during the period. Finally, Kennedy Capital Management LLC grew its stake in shares of Globus Medical by 44.6% in the 3rd quarter. Kennedy Capital Management LLC now owns 490,949 shares of the medical device company’s stock valued at $28,117,000 after buying an additional 151,500 shares during the period. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Insider Buying and Selling

In related news, Director David D. Davidar sold 25,000 shares of Globus Medical stock in a transaction on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the sale, the director directly owned 510,175 shares in the company, valued at $41,201,733. This trade represents a 4.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 18.38% of the stock is owned by corporate insiders.

Globus Medical Stock Down 2.9%

Globus Medical stock opened at $75.29 on Thursday. The firm has a market cap of $10.22 billion, a PE ratio of 17.51, a price-to-earnings-growth ratio of 1.60 and a beta of 0.95. Globus Medical, Inc. has a 52-week low of $51.79 and a 52-week high of $101.40. The company’s 50 day moving average is $85.09 and its two-hundred day moving average is $87.80.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The business had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. During the same period last year, the business earned $0.68 EPS. The company’s revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities research analysts anticipate that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on GMED shares. Piper Sandler lowered their price objective on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a research report on Monday. Barclays increased their price objective on shares of Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Zacks Research raised shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a research report on Wednesday, April 15th. Finally, Needham & Company LLC increased their price objective on shares of Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $105.00.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.